Celastrol slows the progression of early diabetic nephropathy in rats via the PI3K/AKT pathway

Yusong Nie1,2,3, Chengxiao Fu4, Huimin Zhang1

  • 1Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.

Abstract

Insights

Celastrol shows promise in treating early diabetic nephropathy by improving kidney function and reducing blood glucose. It acts through the PI3K/AKT pathway to protect against kidney damage.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic nephropathy is a major complication of diabetes, leading to end-stage renal disease.
  • Celastrol's renoprotective effects and safety profile require further investigation.

Purpose of the Study:

  • To investigate the renoprotective function of Celastrol in an early diabetic nephropathy model.
  • To elucidate the underlying mechanisms of Celastrol's action.

Main Methods:

  • Diabetic rat model induced by high-fat/high-glucose diet and streptozotocin.
  • Biochemical assays (ALT, AST, BUN, creatinine, urinary protein).
  • Histological, molecular, and cellular analyses (PAS staining, ELISA, IHC, RT-PCR, Western blot).

Main Results:

  • High-dose Celastrol improved kidney function, reduced blood glucose and urinary albumin.
  • Increased expression of LC3II and nephrin.
  • Downregulated PI3K, p-AKT, and mRNA levels of NF-κB and mTOR.

Conclusions:

  • Celastrol demonstrates potential as a therapeutic agent for diabetic nephropathy.
  • It acts via the PI3K/AKT pathway to reduce renal injury.
  • Celastrol helps inhibit glomerular basement membrane thickening and maintain podocyte homeostasis.